EUROPEAN Stroke Journal

European Stroke Journal I–8 © European Stroke Organisation 2025

Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/23969873241311152 journals.sagepub.com/home/eso



Aikaterini Anastasiou¹, Alex Brehm¹, Tomas Dobrocky², Adnan Mujanovic², Marta de Dios Lascuevas³, Tomas Carmona Fuentes³, Alfonso López-Frías López-Jurado⁴, Blanca Hidalgo Valverde⁵, Ansgar Berlis⁶, Christoph J. Maurer⁶, Thanh N Nguyen⁷, Mohamad Abdalkader⁷, Piers Klein⁷, Guillaume Thevoz⁸, Patrik Michel⁸, Marius Kaschner⁹, Daniel Weiss⁹, Andrea M. Alexandre¹⁰, Alessandro Pedicelli¹⁰, Paolo Machi¹¹, Gianmarco Bernava¹¹, Shuntaro Kuwahara¹², Kazutaka Uchida¹², Jason Wenderoth^{13,14}, Anirudh Joshi^{13,14}, Grzegorz Karwacki¹⁵, Lehel-Barna Lakatos¹⁶, Agostino Tessitore¹⁷, Sergio Lucio Vinci^{17,18}, Amedeo Cervo¹⁹, Claudia Rollo¹⁹, Ferdinand Hui^{20,21}, Aaisha Siddiqua Mozumder^{20,21}, Daniele Giuseppe Romano²², Gianmarco Flora²², Nitin Goyal^{23,24}, Vivek Batra^{23,24}, Violiza Inoa^{23,24}, Christophe Cognard²⁵, Matúš Hoferica²⁵, Riitta Rautio²⁶, Daniel Kaiser²⁷, Hanna Alph²⁷, Julian Clarke²⁸, Nick Hug²⁸, Alma Koch¹, Victor Schulze-Zachau¹, Nikki Rommers²⁹, Mira Katan³⁰ and Marios-Nikos Psychogios¹

Rescue therapy after failed thrombectomy

in medium/distal vessel occlusions:

international, multi-center registry

A retrospective analysis of an

Abstract

Background: There are limited therapeutic options in cases of failed reperfusion (modified thrombolysis in cerebral infarction [mTICI] score < 2b) after stent-retriever and/or aspiration based endovascular treatment (EVT) for acute ischemic stroke. Despite the absence of data supporting its use, rescue therapy (balloon angioplasty and/or stent implantation) is often utilized in such cases. Studies are limited to large vessel occlusions, while the outcomes and complications after rescue therapy in medium/distal vessel occlusions (MDVOs) have not been reported. This study aims to report the outcomes of rescue therapy in MDVO stroke patients.

Methods: We performed an analysis of the "Blood pressure and Antiplatelet medication management after reScue angioplasty after failed Endovascular treatment in Large and distal vessel occlusions with probable IntraCranial Atherosclerotic Disease" (BASEL ICAD) retrospective registry. All MDVO stroke patients were included in the analysis. **Results:** Out of the 718 registry patients, 87 (12.1%) presented with an MDVO. Fifty-six patients (64.4%) showed an occlusion of the M2 segment of the middle cerebral artery. Rescue stenting was performed in 78 patients (89.7%) while balloon angioplasty alone was performed in 9 patients (10.3%). Successful reperfusion (mTICI score \geq 2b) was achieved in 73 (83.9%) patients after rescue therapy. Symptomatic intracranial hemorrhage (sICH) occurred in 8 patients (9.2%) and post-treatment stent occlusion in 12 patients (13.8%). Ninety days mortality was 20.7%. Twenty-eight patients (32.2%) achieved functional independence at 90 days (modified Rankin Scale 0–2).

Conclusion: Rescue therapy with stenting and/or balloon angioplasty in patients undergoing EVT for isolated MDVO with suspected underlying intracranial atherosclerotic disease is an effective reperfusion strategy but is associated with complications and poor functional outcomes.

Keywords

Acute ischemic strokes, endovascular treatment, rescue stenting, intracranial atherosclerotic disease

Introduction

Acute ischemic stroke (AIS) is a major contributor to mortality and disability, ranking third in terms of loss of quality-adjusted life years.^{1,2} For patients experiencing AIS due to a large vessel occlusion (LVO), endovascular treatment (EVT) has emerged as a standard treatment.³ Over recent years and due to growing confidence with the procedure, EVT is often also extended to patients with medium/distal vessel occlusions (MDVOs), constituting 20%-40% of all AIS cases.⁴⁻⁷ Rapid and complete reperfusion achieved after EVT remains the primary predictor of positive outcomes.⁸ Failed reperfusion (mTICI score < 2b) occurs in 10%-20% of cases, primarily due to underlying intracranial atherosclerotic disease (ICAD), which results in vessel stenosis or in-situ thrombosis leading to instant re-occlusion.^{9,10} It is often observed that after initial successful reperfusion, the artery reoccludes within the time span of minutes. Failure to achieve reperfusion is strongly associated with worse clinical outcomes, with rates of severe disability and death surpassing 70%.¹¹ There is no consensus on the best approach to handle failed reperfusion after EVT.¹²

Rescue therapy with intracranial stenting or angioplasty has emerged as a potential treatment in such cases. Often, AIS from ICAD is caused by thrombosis from an activated atherosclerotic plaque. Thus, even with conventional removal of the thrombus from the occluded site, an activated plaque remains, and re-occlusion can occur. The local recurring thrombus can be potentially treated with the implantation of a stent or with balloon angioplasty alone.^{13,14} (Figure 1) However, this approach has not been evaluated in a large cohort of MDVOs with failed reperfusion. Furthermore, EVT in MDVO is currently under investigation in multiple randomized controlled trials and a matter of debate.¹⁵

In this study we report the outcomes of patients undergoing rescue therapy during the EVT for the treatment of AIS due to MDVO.

Methods

We performed a retrospective analysis of the "Blood pressure and Antiplatelet medication management after reScue angioplasty after failed Endovascular treatment in Large and distal vessel occlusions with probable IntraCranial Atherosclerotic Disease" (BASEL ICAD) retrospective registry. Data were obtained from 32 EVT centers. Adult patients (Age \geq 18 years) were included in the BASEL ICAD registry if they underwent rescue therapy for the

¹⁵Department of Radiology and Nuclear Medicine, Cantonal Hospital Lucerne, Lucerne, Switzerland

Corresponding author:

¹Department of Neuroradiology, University Hospital Basel, Basel, Switzerland

²Department of Diagnostic and Interventional Neuroradiology, Inselspital University Hospital Bern, University of Bern, Bern, Switzerland

³Interventional Neuroradiology, Vall d'Hebron University Hospital, Barcelona, Spain

⁴Interventional Neuroradiology, Hospital Clínico San Carlos, Madrid, Spain

⁵Stroke Unit, Department of Neurology, Hospital Clínico San Carlos, Madrid, Spain

⁶Diagnostic and Interventional Neuroradiology, University Hospital Augsburg, Augsburg, Germany

⁷Department of Radiology, Boston Medical Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA

⁸Stroke Center, Neurology Service, Department of Clinical Neurosciences, Lausanne University Hospital, Lausanne, Switzerland

⁹Medical Faculty, Department of Diagnostic and Interventional Radiology, University Duesseldorf, Düsseldorf, Germany

¹⁰UOSA Neuroradiologia Interventistica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy

¹¹Division of Neuroradiology, Geneva University Hospitals, Geneva, Switzerland

¹²Department of Neurosurgery, Hyogo Medical University, Nishinomiya, Japan

¹³Institute of Neurological Sciences, Prince of Wales Hospital, Randwick, NSW, Australia

¹⁴Prince of Wales Clinical School, University of New South Wales, Sydney, Australia

¹⁶Department of Neurology and Neurorehabilitation, Kantonsspital Lucerne, Lucerne, Switzerland

¹⁷Neuroradiology Unit, University Hospital A.O.U. "G. Martino" - Messina, Messina, Italy

¹⁸Department of Biomedical, Dental and Morphological and Functional Imaging (BIOMORF), University of Messina, Messina, Italy

¹⁹Department of Neuroradiology, ASST Grande Ospedale Metropolitano Niguarda (Niguarda Ca' Granda), Milan, Italy

²⁰Neuroscience Institute, The Queen's Medical Center, Honolulu, HI, USA

²¹University of Hawaii, Honolulu, HI, USA

²²Unit of Interventional Neuroradiology, University Hospital AOU Salerno, Italy

²³Department of Neurology, University of Tennessee Health Science Center, Memphis, TN, USA

²⁴Department of Neurological Surgery, Semmes-Murphey Clinic, Memphis, TN, USA

²⁵Neuroradiology Department, Toulouse University Hospital, INSERM, U1048 and Université Toulouse 3, I2MC, Toulouse, France

²⁶Department of Radiology, Turku University Hospital, Turku, Finland

²⁷Institute of Neuroradiology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

²⁸Department of Neurological Surgery, University of Washington, Seattle, WA, USA

²⁹Department of Clinical Research, University of Basel, University Hospital Basel, Basel, Switzerland

³⁰Department of Neurology, Stroke Center, University and University Hospital of Basel, Switzerland

Aikaterini Anastasiou, University Hospital Basel, Petersgraben 4, Basel 4031, Switzerland. Email: aikaterini.anastasiou@usb.ch



Figure I. Rescue stenting paradigm of an ICAD related occlusion in the M2 Segment of the MCA.

treatment of an LVO or MDVO between January 1st, 2019, and December 31st, 2023. Data from participating centers were curated by reviewing patient charts and procedure notes from the electronic medical records. This registry was approved by the applicable ethics committee (BASEC ID 2024-00904) with a waiver of consent.

For the current analysis only patients who had an isolated primary MDVO were included. We defined MDVO as an occlusion of the co- or non-dominant M2, the M3 or M4 segment of the middle cerebral artery (MCA), the A1, A2 or A3 segment of the anterior cerebral artery (ACA) or the P1, P2 or P3 segment of the posterior cerebral artery (PCA).

The primary clinical outcome was the modified Rankin Scale (mRS) at 90 days, while the primary procedural outcome was the rate of successful reperfusion (defined as a modified thrombolysis in cerebral infarction [mTICI] score of \geq 2b) at the end of the procedure. Secondary outcomes of interest included the National Institute of Health Stroke Scale (NIHSS) at 24h, symptomatic intracranial hemorrhage (sICH) at 24h scored with the Heidelberg Bleeding Classification, post-treatment stent occlusion (within 24h and after day 7) and procedural complications. (Table 1) In addition, we performed a matching of MDVO with LVO patients from the BASEL-ICAD registry with ratio 1:2 using age, NIHSS at admission, pre-stroke mRS, intravenous thrombolysis (IVT), and stenting (vs balloon angioplasty alone) as matching variables. (Supplemental Table 2).

Results

Eighty-seven (12.1%) out of 718 BASEL ICAD registry patients had an MDVO. Seventy-eight (89.7%) underwent intracranial stenting, and nine (10.3%) angioplasty alone. The mean age was 71.6 years (\pm 12.8) and 41.4% were female. Seventy-five patients (86.1%) had a pre-stroke

mRS ≤ 2 (51 of whom were mRS 0) and 11 (12.6%) > 2 (pre-stroke mRS was missing in one patient). The median admission NIHSS was 9 (Interquartile-Range [IQR] 5.5– 14.5). Twenty-four patients (27.6%) received IVT. Median time of onset to groin puncture was 428 [IQR 204–770.5] minutes and median time of onset to recanalization was 508 min [IQR 308–800]. The most prevalent occlusion location was the M2 segment (56 patients, 64.4%). Other occlusion locations were the A1/A2 (7 patients, 8%), A3/ A4 (2 patients, 2.3%), M3/M4 (1 patients, 1.1%), P1 (17 patients, 19.5%) and the P2/P3 segments (4 patients, 4.6%). (see Table 1 for baseline characteristics).

The mRS at 90 days was 0 in 8 cases (9.2%), 1 in 11 cases (12.6%), 2 in 9 cases (10.3%), 3 in 14 cases (16.1%), 4 in 14 cases (16.1%), 5 in 4 cases (4.6%), 6 in 18 cases (20.7%). We had 9 missing values. (Figure 2). Twenty-eight patients (32.2%) achieved a good functional outcome (defined as mRS 0-2) at 90 days. Median NIHSS at 24 h was 9 [IQR 4-17]. The highest mTICI score achieved prior to rescue therapy was 2a or lower in 48 patients (55.1%). The AIS etiology was deemed from the treating physician to be ICAD in 74.7% of the patients (n=65). After rescue therapy mTICI \geq 2b was achieved in 73 (83.9%) patients, while 49 (56.3%) had mTICI \ge 2c. Rescue therapy was performed after a median of 2 (IQR 1-3) EVT passes. (see Table 2 for intervention characteristics). The most used stents were the CREDO® stent (Acandis, Pforzheim, Germany) in 27 patients, the Neuroform Atlas (Stryker, Kalamazoo, US) in 9 patients and the Acclino[®] stent (Acandis, Pforzheim, Germany) in 8 patients. Eighty-three (94.3%) patients received at least one peri-procedural antiplatelet medication: A single agent in 41 (47.1%), two agents in 33 (37.9%) and three agents in 9 (10.3%). (Supplemental Table 1). Efficacy and safety outcomes were not different between patients receiving IVT or no IVT.

Table I. Patient characteristics and outcomes.

Characteristics and outcomes	Overall	M2	M3/M4, ACA, PCA	Missing (%)
Number	87	56	31	
Age	71.6 (12.8)	70.1 (13.6)	74.2 (11.1)	0.0
Sex			(0.0
Female	36 (41.4)	28 (50.0)	8 (25.8)	
Male	51 (58.6)	28 (50.0)	23 (74.2)	
Race				12.6
African American	8 (10.5)	7 (14.9)	l (3.4)	
Asian	5 (6.6)	4 (8.5)	l (3.4)	
White	63 (82.9)	36 (76.6)	27 (93.1)	
Missing	11 (12.6)	9 (16.1)	2 (6.5)	
Hypertension	66 (75.9)	44 (78.6)	22 (71.0)	2.3
Dyslipidemia	29 (33.3)	17 (30.4)	12 (38.7)	18.4
Diabetes mellitus	20 (23.0)	15 (26.8)	5 (16.1)	2.3
Coronary artery occlusive disease	12 (13.8)	8 (14.3)	4 (12.9)	2.3
Current or past smoking	20 (23.0)	16 (28.6)	4 (12.9)	3.4
Atrial fibrillation	9 (10.3)	6 (10.7)	3 (9.7)	2.3
History of stroke or TIA	21 (24.1)	14 (25.0)	7 (22.6)	2.3
Pre-stroke mRS				1.1
0	51 (58.6)	33 (58.9)	18 (58.1)	
I	15 (17.2)	(19.6)	4 (12.9)	
2	9 (10.3)	6 (10.7)	3 (9.7)	
3	9 (10.3)	4 (7.1)	5 (16.1)	
4	2 (2.3)	(1.8)	l (3.2)	
Missing	1 (1.1)	(1.8)	0 (0.0)	
Previous anticoagulation use	7 (8.0)	6 (10.7)	l (3.2)	10.3
Previous antiplatelet use				9.2
No	59 (67.8)	37 (66.1)	22 (71.0)	
Single	18 (20.7)	(19.6)	7 (22.6)	
Double	2 (2.3)	2 (3.6)	0 (0.0)	
Missing	8 (9.2)	6 (10.7)	2 (6.5)	
NIHSS admission	9.0 [5.5, 14.5]	10.0 [5.8, 14.2]	8.0 [5.5, 14.5]	0.0
IVT	24 (27.6)	10 (17.9)	14 (45.2)	0.0
Time onset to groin puncture (min) Occluded vessel	428.0 [204.0, 770.5]	450.0 [212.5, 735.8]	428.0 [203.0, 780.0]	13.8 0.0
AI/A2	7 (8.0)	0 (0.0)	7 (22.6)	
A3/A4	2 (2.3)	0 (0.0)	2 (6.5)	
M2	56 (64.4)	56 (100.0)	0 (0.0)	
M3/M4	1 (1.1)	0 (0.0)	l (3.2)	
PI	17 (19.5)	0 (0.0)	17 (54.8)	
P2/P3	4 (4.6)	0 (0.0)	4 (12.9)	
Occlusion side				2.3
Left	54 (62.1)	35 (62.5)	19 (61.3)	
Right	31 (35.6)	21 (37.5)	10 (32.3)	
Missing	2 (2.3)	0 (0.0)	2 (6.5)	
Etiology rescue stenting				9.2
ICAD	65 (74.7)	41 (73.2)	24 (77.4)	
Dissection	9 (10.3)	6 (10.7)	3 (9.7)	
Hard thrombus	5 (5.7)	3 (5.4)	2 (6.5)	
Missing	8 (9.2)	6 (10.7)	2 (6.5)	
Outcomes				
mKS 90 days			L (2.2)	10.3
U	8 (9.2)	7 (12.5)	I (3.2)	
1	11 (12.6)	9 (16.1) 7 (10.5)	2 (6.5)	
۷	9 (10.3)	/ (12.5)	2 (6.5)	

(Continued)

Table I. (Continued)

Characteristics and outcomes	Overall	M2	M3/M4, ACA, PCA	Missing (%)
3	4 (6.)	12 (21.4)	2 (6.5)	
4	14 (16.1)	8 (14.3)	6 (19.4)	
5	4 (4.6)	3 (5.4)	I (3.2)	
6	18 (20.7)	7 (12.5)	11 (35.5)	
Missing	9 (10.3)	3 (5.4)	6 (19.4)	
Functional independence at 90 days	28 (32.2)	23 (41.1)	5 (16.1)	10.3
sICH	8 (9.2)	4 (7.1)	4 (12.9)	4.6
NIHSS 24 h	9.0 [4.0, 17.0]	8.0 [4.0, 15.5]	13.0 [4.0, 18.0]	11.5
Death	18 (20.7)	7 (12.5)	11 (35.5)	10.3



Figure 2. Distribution of the modified rankin scale (mRS) at 90 days in different distal vessel locations.

In 11 cases (12.6%) intraprocedural subarachnoid hemorrhage (SAH) or vessel perforation occurred. Post- treatment stent occlusion was reported in 12 (13.8%) patients and 8 patients (9.2%) had sICH. The risk of occlusion was higher in patients with postinterventional treatment with a single antiplatelet agent. The 90 day mortality rate was 20.7%. In the matched comparison with the LVO patients form the BASEL-ICAD registry, no significant differences were found. (Supplemental Table 2).

Discussion

The use of EVT is increasingly common in MDVO patients based on extrapolation of strong evidence in the treatment of LVO. This extrapolation extends to the potential use of rescue therapy in such patients. This is, to the best of our knowledge, the first study of rescue therapy in a large cohort of MDVO AIS patients. While it must be taken into considerations that comparisons between studies are to be interpreted with caution due to possible unidentified factors, it appears that outcomes in MDVO patients requiring intracranial stenting or angioplasty are worse compared to the overall population of MDVO patients undergoing EVT.^{16–18}

Good functional outcome was achieved in 32.2% of the patients in the current study. Other studies examining EVT for MDVO patients (with or without angioplasty) have consistently reported higher rates of good functional outcome.^{16,19,20} In the INTERRSeCT/PROVEIT study the rate of mRS 0–2 was 67.4%.¹⁶ The analysis further indicated that excellent outcome (mRS 0–1) was associated with successful early reperfusion. In the HERMES meta-analysis on M2 patients, the rate of good functional outcome was 58.2% in patients undergoing EVT.²⁰

This is despite, the fact that these patients presented with a more severe stroke than those in the current report, and successful reperfusion rates were lower in the HERMES meta-analysis (59.2% in HERMES vs 84.8% in the current report).

Rates of sICH were similar between our study and the INTERRSeCT/PRoveIT registry, while in the HERMES meta-analysis, 0% of sICH was reported. Mortality at 90 days was higher in our study (20.7%) compared to 8.9% in the INTERSECT/PROACT registry and 11.9% in the HERMES meta-analysis.

We hypothesize that the difference in good outcomes seen in EVT for MDVO with rescue therapy are due to one or more of the following: The fact that in our study only MDVOs were included, with possible technical and safety considerations arising from the small vessel size. The overall higher number of passes (since we include a cohort of failed thrombectomies), a higher rate of ischemic or hemorrhagic complications after rescue therapy compared to conventional EVT, and the need for antiplatelet medication to prevent vessel reocclusion. Even with such medication, stent-reocclusion occurred in 13.8% of patients.

Table 2. Intervention.

Characteristics	Overall	M2	M3/M4, ACA, PCA	Missing (%)
Number	87	56	31	
Anesthesia				6.9
General	42 (48.3)	25 (44.6)	17 (54.8)	
Sedation	39 (44.8)	26 (46.4)	13 (41.9)	
Missing	6 (6.9)	5 (8.9)	I (3.2)	
Access site				6.9
Femoral	75 (86.2)	49 (87.5)	26 (83.9)	
Radial	6 (6.9)	2 (3.6)	4 (12.9)	
Missing	6 (6.9)	5 (8.9)	(3.2)	
Highest mTICI achieved prior to rescue			(6.9
therapy				
0	27 (31.0)	20 (35.7)	7 (22.6)	
I	13 (14.9)	8 (14.3)	5 (16.1)	
2a	8 (9.2)	4 (7.1)	4 (12.9)	
2b	16 (18.4)	9 (16.1)	7 (22.6)	
2c	8 (9.2)	6 (10.7)	2 (6.5)	
3	9 (10.3)	5 (8.9)	4 (12.9)	
Missing	6 (6.9)	4 (7.1)	2 (6.5)	
mTICI after rescue therapy			· · /	1.1
0	9 (10.3)	5 (8.9)	4 (12.9)	
I	2 (2.3)	1 (1.8)	l (3.2)	
2a	2 (2.3)		(3.2)	
2b	24 (27.6)	16 (28.6)	8 (25.8)	
2c	15 (17.2)	9 (16.1)	6 (19.4)	
3	34 (39.1)	24 (42.9)	10 (32.3)	
Missing	I(1,1)	0 (0.0)	(3.2)	
Number of passes	2.0 [1.0, 3.0]	2.0 [1.0, 4.0]	2.0 [2.0, 3.0]	2.3
Stenting	78 (89.7)	49 (87.5)	29 (93.5)	0.0
Balloon angioplasty				0.0
No	32 (36.8)	23 (41.1)	9 (29.0)	
Prestent	35 (40.2)	22 (39.3)	13 (41.9)	
Poststent	8 (9.2)	2 (3.6)	6 (19.4)	
Both	3 (3.4)	2 (3.6)	(3.2)	
Alone	9 (10.3)	7 (12.5)	2 (6.5)	
Time onset to recanalization (min)	508.0 [308.0. 800.0]	475.5 [32].5. 763.5]	515.0 [270.0. 830.0]	20.7
Complications]		·····	0.0
No	65 (74.7)	41 (73.2)	24 (77.4)	
SAH/vessel perforation	11 (12.6)	8 (14.3)	3 (9.7)	
Dissection	3 (3.4)	2 (3.6)	1 (3.2)	
Femoral/retroperitoneal hematoma	3 (3.4)	2 (3.6)	(3.2)	
Other	5 (5.7)	3 (5.4)	2 (6.5)	
Post-treatment stent occlusion	12 (13.8)	3 (5.4)	9 (29.0)	9.2
Timing post-treatment stent occlusion				89.7
Within 24h	7 (8.0)	3 (5.4)	4 (12.9)	
After day 7	1(1.1)		(3.2)	
Missing/Not abblicable	79 (90.9)	53 (94.6)	26 (83.9)	
Periprocedural antiplatelets	82 (94.3)	51 (91.1)	31 (100.0)	0.0
Number of periprocedural antiplatelets				4.6
	41 (47.1)	25 (44.6)	16 (51.6)	
2	33 (37.9)	19 (33.9)	14 (45.2)	
3	9 (10.3)	8 (14.3)	(3.2)	
Missing/Not abblicable	4 (4.6)	4 (7.1)	0 (0.0)	
	/	. ()	- (/	

(Continued)

Table 2. (Continued)

Characteristics	Overall	M2	M3/M4, ACA, PCA	Missing (%)
Postprocedural antiplatelets	81 (93.1)	52 (92.9)	29 (93.5)	1.1
Number of periprocedural antiplatelets				5.7
1	14 (16.1)	9 (16.1)	5 (16.1)	
2	68 (78.2)	44 (78.6)	24 (77.4)	
Missing/Not applicable	5 (5.7)	3 (5.4)	2 (6.5)	

Limitations

The limitations of this study are similar to all retrospective studies and mainly stem from the uncontrolled inclusion of patients (i.e. selection bias). A further limitation is the considerable variability in the antiplatelet treatment regimens and their unknown impact on patient outcome. Finally, because no core lab was available, radiological and clinical results were self-adjudicated. The sample size is limited. The most common occlusion site was the non-dominant M2-segment of the middle cerebral artery. The other locations are underrepresented. However, given that we could analyze a large number of patients for a relatively rare procedure, and given the multicenter nature of the registry, this study may meaningfully impact future trials of rescue therapy for MDVO.

Conclusion

Rescue therapy with stenting and/or balloon angioplasty in patients undergoing EVT for isolated MDVO with suspected underlying ICAD is an effective reperfusion strategy but is associated with complications and poor functional outcomes.

Abbreviations and Acronyms

AIS Acute ischemic strokes ACA anterior cerebral artery EVT Endovascular Treatment ICAD intracranial atherosclerotic disease IVT intravenous thrombolysis LVO large vessel occlusion MCA middle cerebral artery MDVO medium distal vessel occlusions mRS modified Rankin Scale mTICI modified treatment in cerebral infarction NIHSS National Institutes of Health Stroke Scale PCA posterior cerebral artery sICH symptomatic intracranial hemorrhage

Acknowledgements

We thank the BASEL ICAD Collaborators for their contribution to this project.

We thank Mr. Eleftherious Remoundos for help with preparation of Figures 1 and 2.

Declaration of conflicting interest

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Victor Schulze-Zachau: discloses speaker fees from Medtronic Inc. (money paid to institution). V.S.-Z. is recipient of research grants from Basel University, Bangerter-Rhyner-Stiftung Basel and Freiwillige Akademische Gesellschaft Basel.

Thanh N Nguyen: discloses Associate Editor of Stroke; advisory board of Aruna Bio, Brainomix.

Kazutaka Uchida: reports lecturer's fees from Daiichi Sankyo, Bristol-Myers Squibb, Stryker, and Medtronic.

Marios-Nikos Psychogios : discloses unrestricted grants from Swiss National Science Foundation (SNF), Bangerter-Rhyner Stiftung, Stryker Neurovascular Inc., Phenox GmbH, Medtronic Inc., Rapid Medical Inc., and Penumbra Inc for the DISTAL trial, grant for SPINNERS trial from Siemens Healthineers AG (money paid to institution) and the following speaker fees: Stryker Neurovascular Inc., Medtronic Inc., Penumbra Inc., Acandis GmbH, Phenox GmbH, Rapid Medical Inc. and Siemens Healthineers AG (money paid to institution).

Other authors declare that there is no conflict of interest.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Ethical approval

Approved by the applicable ethics committee (Business Administration System for Ethics Committees, BASEC ID 2024-00904) with a waiver of consent. The hospital of Bern and Geneva must edit and resend their Data Transfer Agreement document.

Informed consent

Not applicable.

Trial registration

Not applicable

Guarantor

M.-N.P.

Contributorship

A.A., A.B. and M.-N.P. researched literature and conceived the study.

N.R. was involved in protocol development and statistical analysis. A.A. created the cohort, contacted the collaborators and wrote the first draft of the manuscript. All authors reviewed and edited the manuscript and approved the final version of the manuscript.

ORCID iDs

Aikaterini Anastasiou D https://orcid.org/0000-0002-5405-4237 Alex Brehm D https://orcid.org/0000-0002-1630-6210 Adnan Mujanovic D https://orcid.org/0000-0002-6839-7134 Thanh N Nguyen D https://orcid.org/0000-0002-2810-1685 Piers Klein D https://orcid.org/0000-0001-7468-137X Andrea M. Alexandre D https://orcid.org/0000-0002-8080-3916 Agostino Tessitore D https://orcid.org/0000-0002-6163-4328 Christophe Cognard D https://orcid.org/0000-0003-4287-2627

Supplemental material

Supplemental material for this article is available online.

References

- Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012; 380: 2095–2128.
- Feigin VL, Forouzanfar MH, Krishnamurthi R, et al. Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. *Lancet* 2014; 383: 245–255.
- Powers WJ, Rabinstein AA, Ackerson T, et al. Correction to: guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2019; 50: e344–e418.
- Zhao H, Coote S, Pesavento L, et al. Large vessel occlusion scales increase delivery to endovascular centers without excessive harm from misclassifications. *Stroke* 2017; 48: 568–573.
- Smith WS, Lev MH, English JD, et al. Significance of large vessel intracranial occlusion causing acute ischemic stroke and TIA. *Stroke* 2009; 40: 3834–3840.
- Dozois A, Hampton L, Kingston CW, et al. PLUMBER study (Prevalence of large vessel occlusion strokes in Mecklenburg County Emergency Response). *Stroke* 2017; 48: 3397–3399.
- 7. Saver JL, Chapot R, Agid R, et al. Correction to: thrombectomy for distal, medium vessel occlusions: a consensus

statement on present knowledge and promising directions. *Stroke* 2020; 51: 2872–2884.

- Kleine JF, Wunderlich S, Zimmer C, et al. Time to redefine success? TICI 3 versus TICI 2b recanalization in middle cerebral artery occlusion treated with thrombectomy. *J Neurointerv Surg* 2017; 9: 117–121.
- Haussen D, Al-Bayati A, Mohammaden M, et al. The society of vascular and interventional neurology (SVIN) mechanical thrombectomy registry: methods and primary results. *Stroke Vasc Interv Neurol* 2022; 2: e000234.
- Yeo LLL, Jing M, Bhogal P, et al. Evidence-based updates to thrombectomy: targets, new techniques, and devices. *Front Neurol* 2021; 12: 712527.
- Kaesmacher J, Gralla J, Mosimann PJ, et al. Reasons for reperfusion failures in stent-retriever-based thrombectomy: registry analysis and proposal of a classification system. *AJNR Am J Neuroradiol* 2018; 39: 1848–1853.
- Psychogios M, Brehm A, López-Cancio E, et al. European stroke organisation guidelines on treatment of patients with intracranial atherosclerotic disease. *Eur Stroke J* 2022; 7: III–IV.
- Tschoe C, Coffman S, Kittel C, et al. Outcomes after intracranial rescue stenting for acute ischemic stroke. *Stroke Vasc Interv Neurol* 2022; 2: e000129.
- Rodriguez-Calienes A, Vivanco-Suarez J, Galecio-Castillo M, et al. Rescue stenting for failed mechanical thrombectomy in acute ischemic stroke: systematic review and metaanalysis. *Stroke Vasc Interv Neurol* 2023; 3: e000881.
- Marios-Nikos P, Alex B, Jens F, et al. EnDovascular therapy plus best medical treatment (BMT) versus BMT alone for medium distal veSsel occlusion sTroke (DISTAL): an international, multicentre, randomized-controlled, two-arm, assessor-blinded trial. *Eur Stroke J* 2024; 9: 1083–1092.
- Ospel JM, Menon BK, Demchuk AM, et al. Clinical course of acute ischemic stroke due to medium vessel occlusion with and without intravenous alteplase treatment. *Stroke* 2020; 51: 3232–3240.
- Mohammaden MH, Haussen DC, Al-Bayati AR, et al. Stenting and angioplasty in neurothrombectomy: matched analysis of rescue intracranial stenting versus failed thrombectomy. *Stroke* 2022; 53: 2779–2788.
- Strambo D, Michel P, Nguyen T, et al. Endovascular versus medical therapy in posterior cerebral artery stroke: role of baseline NIHSS score and occlusion site. *Stroke* 2024; 55: 1787–1797.
- Nguyen T, Qureshi M, Strambo D, et al. Endovascular versus medical management of posterior cerebral artery occlusion stroke: the PLATO study. *Stroke* 2023; 54: 1708–1717.
- Menon BK, Hill MD, Davalos A, et al. Efficacy of endovascular thrombectomy in patients with M2 segment middle cerebral artery occlusions: meta-analysis of data from the HERMES collaboration. *J Neurointerv Surg* 2019; 11: 1065–1069.